The first Phase 3 study of SKB378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is planned to begin in the first half of 2027...
The approval marks another important milestone in the execution of Everest's commercialization strategy and reinforces the Company's capability to bring innovative therapies to patients in China...
The NDA for indication AD has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA ...
The opportunity to make advanced surgical care accessible to more patients, physicians, and health systems around the world is significant...
CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance...
Fosun International recorded total revenue of RMB86.96 billion. Overseas revenue reached RMB49.16 billion...
The C22 features a 5 kW/110 kHz generator, with pulsed fluoroscopy of up to 40 mA and 30 frames per second (fps)...
Pertussis is a highly contagious acute respiratory infectious disease caused by Bordetella pertussis...
The on-schedule acceptance underscores the Company's disciplined execution of its clinical and regulatory strategy...
The three-day exhibition in northeast China covers medical imaging, in vitro diagnostics, surgical systems, AI healthcare, telemedicine, robotics and hospital infrastructure....
